.png){kind=small}
Jazz Pharmaceuticals was hemorrhaging cash.Their stock crashed to a low of 62 cents.
- Marcus Nikos
- Feb 20
- 27 min read
I was in on JAZZ @ $0.62 Sold @ $165 Don't you wish you were a Client?
Jazz Pharmaceuticals was hemorrhaging cash.
Their stock crashed to a low of 62 cents.
But then, the FDA pulled this controversial move...
And Jazz exploded higher, peaking at $192 a share.
An extraordinary 30,867% gain.
While I can't promise gains that high, Jazz Pharmaceuticals is not alone.
To date, this FDA move has pumped $1.2 trillion into biotechnology companies.
It's why Yahoo Finance says biotech is "one of the best performers of the U.S. stock market."
And get this...
Experts predict another trillion will flood biotech very soon, thanks to this FDA move.
I've identified one company I believe will be at the center of this next round of wealth.
If you missed out on the huge run-up in stocks … get ready:
Wall Street is Bracing for a
New Flood of Biotech Profits
A controversial FDA move could soon unleash another $1.2 trillion into a handful of biotechnology stocks. Here’s why one surprising company is at the center of this next round of wealth.
Most investors have no clue it exists…
Much less how to profit from it…
But a controversial FDA move is fueling a growing bull-run in biotechnology stocks.
It’s created what could be the biggest wealth-building opportunity of your life.
And let me be clear…
This is NOT about Covid-19.
To fight Covid, the U.S. government gave biotech $1.25 billion dollars in stimulus money. $1.25 billion is a lot of money.
But get this…
This FDA move has pumped an estimated $1.2 trillion dollars into biotech. That’s trillion with a T.
In other words, this is 960 times bigger than the Covid-19 stimulus.
It’s a massive amount of money.
And this flood of wealth is driving a biotech boom like nothing we’ve ever seen. Over the last 12 months wave after wave of biotechnology companies skyrocketed in value.
Financial Times called it a “gold mine.”
Yahoo Finance said biotechnology is “one of the best performers of the U.S stock market.”
And check out this headline from Forbes…
“The Record-Breaking Biotech
Funding Tsunami of 2020”
They report this FDA move is so lucrative that venture capital investment in biotechnology just reached the largest levels in history.
Make no mistake.
The savviest investors in the world are going “all-in” on biotech.
And some are already cashing in.
I’m talking about the original investors in Apple… a founder of PayPal… and even the world’s richest man, Jeff Bezos.
They’ve made billions off this trend… and plan to make billions more…
I’ll show you how in a moment.
And let me assure you, you have NOT missed out on the lion’s share of profits.
But you must act right now.
You see, the money rushing into biotechnology stocks thanks to this FDA move is…
Growing at an exponential pace!
Which means the outsized returns to investors we are seeing today will get much bigger.
And here is the proof…
Evaluate Pharma crunched the numbers.
They are the gold standard for pharmaceutical industry reporting. They looked into how much money biotechnology companies generated thanks to this FDA move.
Here is what they found.
As you can see, it’s increased every single year.
And if you look back… and… add up the amount each year from 2010 to 2020, it comes out to $1.2 trillion dollars.
$1.2 trillion in revenue over the last decade.
A staggering amount.
But look at the revenue predictions going forward.
$192 billion in revenue in 2021.
The next year, $216 billion.
Then $240 billion.
$262 billion.
And a whopping $294 billion in 2025.
Put it all together and that’s…
An additional $1.2 trillion dollars over the next five years
Bottom line…
This trend is accelerating.
And that’s why I’m here with you today.
Over the next few minutes, I’d like to share with you the details of this FDA move…
And how you could personally profit today, tomorrow, and for years to come as this next $1.2 trillion dollars flows into biotechnology stocks.
Now before we dive in, let me make one thing clear.
Not all biotechnology companies stand to profit from this FDA move. There is a strict qualification process.
But those companies that meet the FDA’s requirements are some of the best investments in biotech.
Specifically, I’ll show you how this FDA move is behind 9 of the top 10 best-selling biotech’s of this century. These are companies that have ALL generated over $100 billion dollars EACH.
And you’ll also get details on top biotech recommendation that stands to benefit from this FDA move.
There is a LOT to love about this company.
The FDA already green-lighted six of this company’s cures.
And they could secure a record-setting 7th FDA approval…7th!... which – if history is any indication – could send their stock soaring again.
Now, if that was ALL this company had going for it, they would be a screaming buy.
But that doesn’t even begin to scratch the surface of why I’m excited.
You see, during development of their first six FDA-approved therapies, they made what could be the biggest medical breakthrough of this century.
I’ll tell you all about it later…
But as a result, EVERYONE in biotech is rushing to partner with or acquire them.
Which is why I have to give you this fair warning
This presentation could be removed at any time.
Between the potential FDA approval of its 7th cure… its huge breakthrough… and increasing popularity…
It could quickly soar out of my “buy up to” range… or… be bought out at any moment.
The second this happens; this opportunity will disappear forever.
There’s not a second to waste.
And even if you don’t invest a penny in this company, I urge you to watch this presentation until the end.
Because what you’re about to see is already putting an end to suffering… reversing disease… and unleashing almost superhuman health, at any age.
What you discover here could save your life, or the life of a loved one.
I’ll circle back to this company’s incredible breakthrough shortly.
But first, a moment ago, I promised to show you just how lucrative this FDA move could be for shareholders.
I will now fulfill that promise.
FDA move delivers billion dollar returns
Do you know who Peter Thiel is?
He’s a billionaire venture capitalist.
He co-founded Paypal. He got in early on Facebook. He made 200,000% on that investment.
Thiel is one of the top VC’s on the planet.
Recently, he’s been very active in biotech. A few years back he made the largest bet ever in the history of his VC firm.
It was on a tiny biotech company.
And everyone thought he was nuts.
Why?
MIT’s Technology Review called it “all but unheard of.” It had no product on the market. No revenues. It was burning through cash.
But it did have something going for it.
It was on the receiving end of this FDA move.
Soon after, AbbVie – the massive pharmaceutical company – bought them out for $5.8 billion dollars.
And Thiel’s firm made a cool $1.4 billion-dollar profit.
Thiel’s not the only insider getting richer.
The richest man in the world is, too.
I’m talking about Jeff Bezos.
His VC firm, Bezos Expeditions, invested in a little-known company called Juno therapeutics that benefited from this FDA move too.
Pharmaceutical giant Celgene later bought it for $9 billion dollars.
This personally made Bezos – already the world’s richest man – $4.1 billion dollars richer.
And then there’s the legendary venture capital firm that funded Yahoo and Apple among others… Sequoia Capital.
Now, they’re going all in on biotech’s that qualify for this lucrative FDA move.
They backed a little company called Amylin. Out of nowhere, it sold to Bristol Myers Squibb for $5.3 billion.
They invested in Onyx pharmaceuticals which sold to Amgen for $10.5 billion.
And then there’s BridgeBio. When it went public their stake skyrocketed 3,764%.
Enough to turn a $1,000 investment into over $376,000.
Now, these are the financial elite…
With inside information not available to the average investor.
So results like this are not typical.
But they are happening right now.
And thanks to this FDA move, you have the opportunity to get in on one of the most-powerful wealth building trends I’ve ever seen.
A trend that everyone in venture capital believes could be one of the most lucrative investments in the coming years.
To illustrate that point…
Do you remember this Forbes quote I showed you a moment ago?
“The Record-Breaking Biotech Funding Tsunami of 2020”
They report VC funding is at an all-time high.
Take a look at this chart…
It shows they invested $34.6 billion into biotechnology in 2020.
That’s up from $8.1 billion in 2010.
Said differently, a 327% increase over the last decade.
It’s a massive increase in investment.
And it’s already starting to pay off.
You see, VCs typically invest in private companies. And then generate huge returns when those companies go public… in what’s called an initial public offering.
An IPO.
Well, 2020 was one of the hottest IPO years on record.
426 companies went public.
That’s more than any time in the last 20 years.
And get this…
More than HALF of companies going public were in healthcare or biotech companies.
It’s an absolute frenzy.
And VC’s are investing all this cash NOW…
Because they are betting they’ll profit for years to come as this next $1.2 trillion flows into biotechnology.
So that begs the question…
Where is all this VC cash going? What does it have to do with this FDA move? And why could it turn a tiny stake into a huge nest egg?
New drugs, bigger profit potential
The answer starts in a tiny sliver of the overall biotechnology market.
If you guessed drugs, you’re right.
But not just any type of drug though.
ONLY an emerging new class of drugs.
They account for less than 8% of all drug sales. Barely a blip on the radar of total healthcare spending. But that’s where this FDA move comes in.
You see, the FDA wants MORE of these special types of drugs.
So they created a special incentive that makes creating these drugs the MOST profitable thing biotechnology companies can do.
Here’s how it works.
If a biotechnology company develops one of these special types of drugs, the FDA can issue it an unusual “guarantee”.
What do they guarantee?
Complete exclusivity in the market for that special new drug.
Which means nobody else can sell a drug like it.
In other words, ZERO competition.
And because the market for these drugs can be worth billions of dollars per year this FDA guarantee can be extremely lucrative.
So it should come as no surprise that when a biotech company receives it, their value can skyrocket like nothing else in the stock market.
And investors who get in early are in for the most exciting ride of their lives.
Just look at what happened to Alexion Pharmaceuticals.
For years they traded sideways.
But then their new blood disorder therapy earned the FDA guarantee. And the stock took off, from just $3.60 to a high of $204.30.
That’s a max gain of 5,575%... turning every $1,000 into $56,750.
Here’s another example. Questcor.
They hovered at less than a buck a share.
But then they solved a brutal condition that causes uncontrollable seizures in babies.
They too got the FDA guarantee. And the stock soared an astonishing 10,416% before they were acquired in a massive $5.6 billion buyout.
Now it’s incredibly rare for any single investment to add a pair of zeroes to your bottom line…
But that turns a tiny four-figure $1,000 investment into a six-figure $100,000 windfall.
And look at what happened to Jazz Pharmaceuticals…
Hemorrhaging cash, their stock crashed to a low of 62 cents.
Critics thought they were done.
But then their FDA guaranteed treatment for epilepsy hit the market.
The result?
Jazz exploded higher. Peaking at $192 a share just a few short years later.
That’s an astonishing 30,867% gain.
Enough to turn $1,000 into over $300,000. That would pay for some people’s retirement in full. They’d be set for life.
I could show you hundreds of examples where this FDA guarantee could have turned a tiny grub-stake into a six or seven-figure fortune.
2,215% when a Novo Nordisk treatment for bleeding got FDA guaranteed.
6,360% when Incyte’s bone cancer treatment got FDA guaranteed.
15,682% when Teva Pharmaceuticals’ multiple sclerosis treatment got FDA guaranteed.
Now I can’t promise gains this high…but over and over again, when a biotech gets this FDA guarantee the potential profits are like nothing I’ve ever seen.
In fact, this FDA guarantee is behind some of the biggest fortunes in biotech.
Take a look…
This is a list of the top 10 best-selling drugs of the 21st century. They’ve all generated over $100 billion dollars in sales. Not $100 billion combined. $100 billion each.
Notice: some are highlighted.
They received the FDA guarantee.
Incredibly…
As you can see, 9 of the top 10 received this FDA guarantee before going on to generate billions in revenue.
The final five…
Remicade, Epogen, Herceptin, Avastin, Advair… all over $110 billion in sales EACH…
That adds up to $1.1 trillion. All tied to this FDA guarantee.
A trillion dollars. And nobody is talking about it!
It’s a mountain of money…
Investing in any one of the companies behind these drugs could have paid for a lavish retirement.
But get this.
That’s just from these 9 drugs.
There are currently 147 drugs on the market with this FDA guarantee with many more coming down the pipe. Making this tiny sector the fastest growing sector in medicine… being approved at rate 4X more than regular drugs.
Can you now see why there’s such a mad dash to own a piece of these companies?
The money rushing in is faster than ever before…
And thanks to this FDA guarantee, VCs know there’s essentially a golden ticket to massive amounts of accelerated wealth.
Today I’ll share full details on this FDA guarantee.
Why it’s poised to make traditional pharmaceutical companies obsolete.
Send current treatments to the dustbin of history.
And change the future of healthcare.
You’ll see how it’s not only curing disease and savings lives, it’s set to…
Start a revolution in the $3.6 trillion dollar healthcare industry.
Create millions of new high-paying, skilled jobs.
And mint a whole new wave of millionaires.
In a moment, you’ll see why the FDA guarantee is driving decisions at every level in biotech and full details on the wealth at stake.
In fact, and you can quote me on this, this is the most lucrative trend you’ll ever come across as an investor.
And it’s all thanks to an unusual guarantee made by one of the biggest regulating authorities of the federal government… the FDA.
But before I go any further, let me tell you a little bit more about who I am and why I’ve reached out to you today.
As you’ll see, this biotech bonanza is quickly passing you by.
I find the trillion-dollar tech trends before anyone else
Ran money on Wall Street
Now I publish a series of newsletters focused on opportunities in all areas of technology.
And I believe I’ve been able to attract such a large following for a reason.
You see, good investment advisors spend their entire professional careers studying the financial side of running a business.
Profit and loss statements… spreadsheets… earnings reports… things of that nature.
That’s incredibly important.
But when it comes to successfully investing in technology – biotech or otherwise – experience matters.
And let me assure you, the technology behind everything running our lives is incredibly complex.
Self-driving cars…
Quantum computing…
Artificial intelligence…
Cyber security…
Biotech…
To most people in the investment word, these are buzzwords.
To me they are my stock and trade.
This combination helps me spot profitable tech trends before they hit the mainstream.
For instance, in the 90’s I got into a tech company called Infospace and made 743% in three days.
Then there’s Intabio. They help biotechnology companies get FDA approval faster.
As of this writing my stake is up 1,600%.
And in 2015, when a front-page Washington Post headline slammed Bitcoin, calling it “a pyramid scheme”…
I told my subscribers to buy.
The rest as you know, is history.
Cryptos surged… and subscribers who followed my advice had the opportunity to experience 8,200% gains.
Enough to turn every $1,000 invested into $82,000.
That’s more than most people make in a year of working.
The next year, in 2016, I told subscribers to buy computer chip manufacturer NVIDIA.
My time running NXP Semiconductors in Japan gave me unique insight into the semiconductor market and I knew NVIDIA was going to have a breakout year.
It went on to become the #1 stock of the year.
And subscribers who followed my lead could have 20x’d their money if they held on.
The next year, in 2017, my research pointed to computer processor company AMD. It topped the NASDAQ 100 in 2018 AND 2019.
And more recently, my recommendation NVIDIA went on to become the top tech investment of 2020.
In other words, I picked the top tech investments of 2016, 2018, 2019, and 2020.
And it’s all because my lifelong dedication to studying, understanding, and deciphering the impact technology will have on our lives.
But as crazy as it sounds – the months ahead could be even better.
I firmly believe we’ve entered the decade of biotech, and FDA guaranteed biotechnology companies will mint more millionaires than any financial trend in history…
And some subscribers have already reported taking my prediction to the bank.
You see, on October 29, 2019, I recommended Synthorx.
Most people didn’t know it existed. But less than two months after I recommended it, pharmaceutical giant Sanofi bought it for a whopping $2.5 billion.
Now this is important…
Sanofi’s entire business model is geared exclusively towards obtaining this FDA guarantee for various therapies.
Readers who strictly followed my recommendations had the chance to pocket 432%... more than quadrupling their gains in less than two months!
That transforms every $1,000 into over $5,000.
And don’t think you’ve missed out on the lion’s share of this biotechnology boom.
Because there couldn’t be a better time to get in…
You can get started with a few hundred dollars… but to have a chance at getting the biggest returns… you must know exactly what this FDA guarantee is.
And more importantly, why it matters right now.
It starts with the biggest medical breakthrough of this century
Prestigious institutions the world over are calling it the next revolution in medicine.
Harvard considers it “the hottest and most promising area of medical research.”
Stanford says they hold the key to “curative therapies to a range of diseases that currently have no cure.”
And look what Bill Gates is saying about it…
The National Institutes of Health have set aside a mind-boggling $10.4 billion dollars to research it in 2021 alone.
That’s more than ANY other disease.
More than what’s budgeted to research cancer, Alzheimer’s, diabetes, and heart disease.
What could possibly be more important than focusing on the LEADING causes of death in the United States?
Of course, I’m talking about genetic therapy.
It is our nation’s top priority because experts worldwide – including myself – agree the ability to alter the human genome will one-day put an end to all disease.
It’s the holy grail of medicine.
Just like the invention of antibiotics a century ago wiped out the world’s deadliest infectious diseases…
I’m talking about pneumonia, staph infections, smallpox, syphilis, typhoid fever, and the list goes on…
One day you’ll be able to walk into a doctor’s office… get a genetic test… and walk out with a pill that conquers any genetic deficiency you have.
A lifetime free from disease.
How much would a pill like that be worth to you?
A one-time solution for a lifetime of immunity from defects in your genetic code…
Defects that cause pain...
That cause disease...
That reduce your quality of life...
That could cut your life short by 10, 20, maybe 50 years?
Defects that you would otherwise pass down to your children?
How much would a pill like that be worth?
$100?
$1,000?
A million?
More?
Time will tell…
But the companies behind these genetic therapies will change what we thought was possible from medicine.
Investors in these companies could grow rich beyond their wildest dreams.
And in the process, make the world a much better place for people suffering from the worst diseases imaginable.
In fact, it’s already happening…
Genetic therapy gives little girl new lease on life
For example, earlier this year Scientific American shared the story of little Emma Larson.
At just 13 months old her muscles began failing her.
As a father, stories like this break my heart.
At a time when most parents see their children walk for the first time, Emma was going backwards. She could barely even crawl any more.
She suffered from a disease called spinal muscular atrophy.
But get this…
The disease is caused by a defect in a gene called SMN1.
Well, Ionis Pharmaceuticals developed a drug to fix it.
And after just three doses, look what happened next.
Scientific American wrote Emma’s mother Dianne was in her bedroom when it happened.
She heard Emma calling her from the nearby den. It was getting closer and closer. And Diane said, “Next thing you know she’d crawled from the den all the way to my bedroom.”
Dianne was floored.
Her daughter was getting better.
She asked herself, “Did I just see this?” So Dianne picked her daughter up and carried her back down the hall. Then she returned to the bedroom and called, “Emma, come here.” And then the little girl crawled into her mother’s arms again.
It’s a miracle.
A handful of treatments fixed the faulty gene. And a little girl now has a chance to walk again.
Stories like this illustrate the incredible future that will be made possible by genetic therapy.
And the incredible investment opportunities in front of us...
In this case, had you invested in Ionis Pharmaceuticals when the drug that cured little Emma secured the FDA guarantee, you could have realized a gain as high as 802%.
That turns a $1,000 investment into $9,800. And transforms $10,000 into close to one hundred thousand dollars.
And this is just the beginning, because…
Genetic therapy is quickly dominating the
$3.6 trillion healthcare market
Soon every man, woman, and child on earth will know exactly what’s going on in their genetic code… and what to do to fix it…
Just look…
In 2001, you had to have Bill Gates-level wealth to get your genome sequenced. It cost $100 million.
But thanks to improving technology…
The National Human Genome Research Institute, a division of the National Institutes of Health, reported in May 2019 the cost dropped to just $600!
That’s a pace faster than “Moore’s Law!”
Which means now almost everyone can afford it.
In fact, some insurance companies now even pay for it!
As a result, over a million Americans have now had their genome sequenced. And that number is expected to soar to 60 million by 2025.
That’s almost 18% of the U.S. population….
And just to give you an idea of the scope of this change…
The first personal computers hit the market in the mid ‘70s. By the time Apple released the first Macintosh roughly a decade later, personal computers were in 8% of U.S. homes.
Said differently…
Americans are adopting genetic sequencing technology more than TWICE as fast as personal computers…
In half the time!
Imagine if you bought any of the major players in the computer market in the 1980s, when it was just on the cusp of widespread adoption.
You’d be sitting on a goldmine.
That’s the opportunity available right now, in genetic therapies.
Of course, not every computer company from the 1980s made investors multi-millionaires. So how do you possibly find companies worth investing in now?
That’s where the FDA guarantee comes in…
Officially it’s called the Orphan Drug Designation.
The FDA created it in 1983 to incentivize companies to develop drugs for genetic mutations that cause orphan diseases.
What are orphan diseases?
These are incredibly rare diseases like the one little Emma had.
Typically, they affect less than 200,000 people.
But when you combine ALL of the orphan diseases together, they affect a large swath of the population.
About 30 million Americans.
How does a biotech company get one of these orphan drug designations?
In short, if early results indicate a biotech’s new treatment could – key word here is could, not will... COULD — be the cure for an orphan disease…
The FDA will guarantee seven years of exclusivity from the time the drug hits the market.
In other words, seven years to sell the drug with zero competition.
Seven years of no competition is a HUGE advantage… an almost insurmountable advantage. And get this…
Orphan drug designation is NOT unique to the United States
Many more countries have incentivized companies to make drugs more widely available for orphan diseases.
According to one Harvard University study, 26 countries “have implemented a combination of legislations, regulations and policies for orphan drugs in the last two decades,” that “enable the availability and access to orphan drugs.”
And following the United States’ lead, they too offer a guarantee of exclusivity.
What that means is this is a worldwide phenomenon.
And if you are a serious investor, this is something you simply can NOT ignore.
Because just like advances in technology over the last twenty years made everything around us better, faster, and cheaper…
Faster computers… better cell phone reception… smart cars, smart homes, smart everything… all affordable for every man, woman and child…
Triggering an incredible bull run in technology…
Advances in technology are about to accelerate everything possible with genetic therapy.
It started with the sequencing of the human genome, which was finished in April 2003.
Then came the ability to edit that genetic code with CRISPR a decade later.
And now with complementary technologies like machine learning… artificial intelligence… big data and much more… throwing fuel on the fire…
The dream of the genetic therapy revolution is charging ahead full steam.
And combine that with the massive financial incentive guaranteed by the FDA’s orphan drug designation…
A bounty awaits for investors who position themselves now.
You see, biotech companies are increasingly pursuing the incredibly lucrative orphan drug designation.
Just look…
Designation have more than quadrupled since the human genome project was completed.
And combine that with the fact it is simply easier, faster, and much more profitable than traditional drug research, and the opportunity in front of us is unparalleled.
Consider this…
We’ve been developing drugs for heart disease for 100 years and it’s still the leading killer in the United States.
President Richard Nixon started the “War on Cancer,” in 1971… and we are no closer to a cure now then we were then.
And the last FDA approved drug for Alzheimer’s came out in 2003. That’s almost 20 years ago!
In short, creating drugs for traditional diseases has proven incredibly difficult.
They are typically caused by a variety of factors. Age, lifestyle, and genetics all come into play. That makes them almost impossible to treat, much less cure.
Contrast that to orphan diseases like the one little Emma had.
That can be traced back to ONE faulty gene.
That can be cured with just a few treatments… sometimes even a SINGLE treatment.
With drugs that can be created, perfected, and approved faster than ever thanks to new technology.
And also come with an FDA guarantee
It’s a no-brainer.
And as these next generation of medicines trickle into the market NOW is the time for investors to position themselves for maximum profits.
You see as of right now there are over 10,000 human disorders caused by gene mutations.
There is currently NO known cure for them. And each one is worth hundreds of millions of dollars a year.
Said differently…
If they are anything like the Ionis drug that cured little Emma…
That’s 10,000 opportunities for investors to experience
800% gains in the very near future!
I’ve written a special report that outlines the opportunity in front of you. It’s called The Next King of Biotech: Unlocking the Genetic Therapy Revolution.
It includes my #1 FDA guaranteed biotech pick.
This company has solved the single biggest limitation of genetic therapy.
It’s a problem that’s plagued the entire genetic therapy revolution from the start.
Here it is…
For decades, we've heard the word "could" associated with genetic therapy.
If you “could” simply fix the gene associated with any of these 10,000 known genetic diseases, you “could” cure the disease… for life.
But until now, there was no reliable way to do this.
That’s because while it’s now relatively easy to IDENTIFY the missing or mutated genes associated with these 10,000 diseases…
It’s quite another thing to FIX that missing or mutated gene.
After all, your genes are hidden deep within the DNA of every one of your cells.
And your body is a fortress.
Even if you had a drug that could fix a faulty gene, it would do ZERO good if you can’t get it to your cells.
It’s a herculean task.
Your skin… your lungs… your kidneys… your liver… your immune system… and so much more… there are multiple layers of protection. All designed to stop anything that looks like a threat from getting to your cells.
The trick now is NOT identifying which genes are broken.
And it’s not even that difficult to make the drugs to fix these genes…
The problem now is how do we get that drug through the multiple defenses of your body.
It’s the single biggest limitation stopping the revolution of the next generation of medicines
And that’s why I'm so excited about my #1 pick.
Like I mentioned, they’ve gotten FDA approval for SIX drugs that fix genetic mutations. An amazing feat.
But more importantly…
During that process they’ve developed, perfected, and filed patents for a new delivery method for these new drugs.
I don’t have time to dive into the nitty gritty science of how it works.
Besides, the details are all outlined in The Next King of Biotech: Unlocking the Genetic Therapy Revolution report. And I’ll give it to you for free. More on that in a moment.
But for now, all you need to know is my #1 pick has proven it works multiple times… as evidenced by their first six FDA approved drugs.
And more importantly…
They’ve just finished building one of the largest facilities of its kind to produce this delivery mechanism.
This is key.
Because without this special delivery mechanism…
And the ability to produce it at scale to treat the millions of people with genetic diseases…
The entire field of genetic medicine could be dead in the water
Genetic Engineering and Biotechnology News reported on the problem in February 2020.
They interviewed Dr. Jerry Keybl, who is head of the cell and gene therapy manufacturing division at major industry supplier MilliporeSigma.
He admitted “manufacturing capacity shortages are still a challenge.”
The same question was addressed to Dr. Hanna P. Lesch, the gene therapy unit director at the Kuopio Center for Gene and Cell Therapy in Finland.
She said, “All experienced contract manufacturing organizations are fully booked.” She also indicated that the shortage in manufacturing capacity is “a generally known situation.”
Note the phrases…
“Manufacturing capacity shortages”…
And “fully booked”.
In short, all these biotechnology companies developing genetic drugs need this delivery mechanism. But it’s incredibly hard to make them.
It’s a classic supply and demand problem.
It presents research problems (you can’t test genetic therapies without it).
It presents approval problems (both the genetic therapy AND the delivery mechanism need FDA approval… making the process take longer).
And it presents problems of producing these medicines at scale…
After all, if there is not enough of this delivery mechanism, then there is not enough medicine for patients.
How big is the problem?
The New York Times reports…
Did you catch that?
The few manufacturing companies are booked up years in advance… AND… they take a cut of the profits from every drug that is sold!
You can imagine how much this can dig into the profitability of a company.
And this is the key competitive advantage of my #1 pick.
They built their own facility to manufacture this delivery mechanism.
Which means…
They don’t have to compete to secure manufacturing contracts.
They don’t have to wait years for those contracts to be fulfilled.
And they don’t have to pay out a lifetime of royalties after the fact.
Plus…
It’s one thing to be able to produce a drug.
Quite another to produce it at a scale that maximizes profits.
Think Coca-Cola.
They aren’t a $226 billion dollar a year company because they are good at making sugar water.
They are a $226 billion dollar a year company because they created and control the global supply chain that delivers the lion’s share of the world’s soda.
Likewise…
This company has positioned itself to make the next generation of medicines…
AND to be the main supplier of the delivery mechanism needed to make these new drugs work.
All 10,000 of them.
So how much money could this make you exactly? The good news is that we don’t have to guess.
History shows the sky is the limit.
When a company develops a new drug delivery system,
the wealth created can be enormous
Take vaccines for example.
Vaccines as a class of drugs are one of the greatest medical advances in history. They’ve largely eliminated the worry for debilitating and deadly diseases like polio, measles, and more…
But you’ve probably never given much thought to the packaging vaccines come in.
I’m talking about glass vials. Specifically, the little pieces of rubber on the end that keep them closed.
You’ve seen them at your doctor’s office.
They are used by the billions in laboratories around the world… for transporting blood, drugs, vaccines, and other precious fluids.
They seem simple. Almost an afterthought.
But get this…
It turns out these rubber stoppers can leach chemicals. And this can drastically diminish a vaccine’s potency.
That’s where West Pharmaceuticals comes in.
In 2016, they released a better version of this rubber stopper.
Why?
It doesn’t leach chemicals.
This makes it more effective to use for vaccines.
In short order the FDA approved it for use in over 125 drugs, including vaccines. And they quickly became the industry standard.
Over the next few years the stock crept higher. From a low of $40 in mid-2015 to a high of $149 in 2019.
Had you gotten into West Pharmaceuticals at the beginning of their bull run you would have nearly quadrupled your money.
To put that into perspective, that’s better than Apple during the same time period.
It’s incredible. And any investor should be thrilled with those returns.
But it was just a taste of what was to come.
In 2020, Covid supercharged vaccine interest. And thanks to the new and improved rubber stoppers, West Pharmaceuticals stock went nearly vertical… hitting almost $300 a share.
That’s a gain of almost 650%.
In just a few years, turning every $1,000 invested into $7,500.
For investors, that’s the benefit of getting into companies that create new drug delivery systems
Competition is a GOOD thing.
As more and more breakthroughs occur, new drug companies turn to the leader in the field to deliver their new cures.
Just like my #1 pick is doing.
Another example is one of the most widely used drugs in the world.
Insulin.
Insulin controls fluctuations in blood sugar. It’s a lifesaver to the roughly 200 million diabetics worldwide who need it to survive.
But insulin is time-consuming and painful to administer.
You have to prick your finger to take blood. Then put it through a little device to check blood sugar levels. And finally, shoot in the right amount of insulin with a needle.
Sometimes multiple times per day.
That all changed when the Insulet Corporation introduced a device that does that automatically.
It’s called the Omnipod Dash Insulin Pump.
With just a cell phone, it monitors blood sugar and administers insulin automatically… with no input… for up to 3 days.
A huge time-saver for diabetics.
And a huge game-changer for Insulet’s share price.
Hovering around the $30 mark for years…
Their stock soared when they announced their latest generation Omnipod in 2017… peaking at $97 when it gained FDA approval the next year.
A gain of 233%.
The market welcomed Omnipod with open arms. And Insulet continued its tear, rising to a peak of $249 in 2020.
That’s 730% gains in just a few years.
I could go on…
Of course, past performance does not guarantee future success.
You should never invest more than you could stand to lose.
But that’s why I'm so excited.
My #1 pick holds the key to unleashing the genetic revolution.
It's developed the optimum delivery mechanism for genetic therapies…
Proven to work with SIX FDA approved genetic drug cures…
ALL orphan drugs... a tiny sliver of the drug market that’s set to receive another $1.2 trillion over the next five years.
And by building the biggest genetic delivery mechanism manufacturing plant the world has ever seen… they’ve put themselves smack dab in the middle of this coming flood of wealth.
This is why I assembled a new report on this opportunity.
Complete with its name, ticker symbol, and full company profile…
And full details on this trillion dollar genetic medicine revolution…
I call it:
The Next King of Biotech: Unlocking the Genetic Therapy Revolution
As of today, anyone with a standard brokerage account can secure shares in it well below my buy up to price.
With your permission, I will send it to your inbox, completely free of charge.
All I ask in return is that you give my flagship newsletter a risk-free test drive.
Called The Near Future Report…
The goal of this research service is simple:
To help ordinary people learn how to make profits on breakthrough technologies on the verge of mass adoption. Trends that are far too complex for the mainstream press to understand… much less help you profit from.
I’ve shown you a few of the triple-digit gains my readers could have locked in…
And right now in my portfolio of open recommendations… 27 of my 29 recommendations have posted gains.
That’s a winning rate north of 92%.
These are not boring, stodgy picks you’ll hear about in the mainstream media.
These are the future technologies that will power our world. And generate long-term growth for your retirement portfolio.
And because of my vast experience, I’ve been told no one else in the industry delivers high quality technology investment advice like I do.
In addition to your free report, The Next King of Biotech: Unlocking the Genetic Therapy Revolution, here’s what you’ll get with your membership to The Near Future Report…
12 issues of The Near Future Report – Delivered every month, each issue is packed with the best technology investments I uncover. 5G, artificial intelligence, self-driving cars, biotech and much more. You get it all.
My latest investment research – You’ll get complete updates on how breaking tech news affects world markets and your portfolio.
Carefully chosen opportunities – And priority access to my next biggest opportunities.
And a bundle of special reports on the hottest developments in technology today like…
Bonus Report #1: The New Economy: 5 Stocks that Will Soar in the “Post-Covid” World. Over the past 24 months I’ve shown readers gains as high as 181%, 290%, 339%, 34%, 106%, 87% and 108% by capitalizing on changes in 5G, artificial intelligence, cloud computing, cryptocurrency, future transportation, and yes, precision medicine. The 5 companies inside this report have the potential to do that and more.
Bonus Report #2: Toxic Tech: 5 Tech “Darlings” to Dump Right Now. Wall Street loves these 5 Tech “Darlings,” but in this report I’ll reveal why you must purge them from your portfolio before they ruin your retirement.
Bonus Report #3: Project Xi: Two Explosive Stocks Behind the $15 Trillion Tech Revolution. Covid made it clear. Manufacturing needs to return to America. We can no longer rely on China to supply essential goods like the electronics used by our military… the machinery used to run our factories… and the medicine to keep us alive. In this report I reveal my two top picks for this next generation of “Made in the USA” companies.
What does all this cost?
Well, to put together this quality of research costs me a small fortune.
And I employ a small army of analysts who also criss-cross the country too, investigating the latest investment opportunities in tech.
There is simply no replacement for this firsthand, in-the-trenches research.
And as you can imagine, this type of quality reporting does not come cheap.
For instance, this is a report on the value of the Global Orphan Drug Market.
It was written by a research firm that caters to pharmaceutical executives.
And it costs $4,000.
One report, $4,000!
Frankly, considering the tremendous financial opportunity in front of us in biotech, I believe it’s worth every penny.
But $4,000 is out of reach for the average investor.
Which is why I’m not charging anywhere near that amount.
On our website, a one-year subscription to The True Future Report costs $199.
For years, $199 was the minimum I’d ever consider selling my research for… it’s just too valuable to give away for anything less.
But because of the magnitude of what’s happening in the biotechnology market today, I’m slashing that price even further.
And again, please do NOT go to our main website. I repeat. Do NOT go to our main website, you’ll have to pay full price.
Instead, if you sign up right now, on this special page you can take advantage of a once-in-a-lifetime offer.
By agreeing to take a subscription to The Near Future Report, you’ll save $150 instantly… and pay just $49 for an entire year’s subscription.
I believe no one else on the planet can deliver high quality technology investment advice like I can.
But I’ll invite you to make that decision for yourself.
Subscribe to The True Future Report today.
Read my special report The Next King of Biotech: Unlocking the Genetic Therapy Revolution.
And the other special reports.
The genetic medicine revolution is happening right now.
The FDA guarantee has made it incredibly lucrative.
And the opportunity to invest in companies on the leading edge of it is red-hot.
Those that have secured this FDA guarantee have generated hundreds of billions in sales, becoming the biggest companies of the 21st century.
Others have seen their stocks soar 5,575%... 10,416%... and 30,867%.
And they just have single cures.
But the company in The Next King of Biotech: Unlocking the Genetic Therapy Revolution has SIX cures… all FDA approved…
Is on track to receive a record-setting 7th…
And more importantly, holds the key to unlocking the genetic revolution for everyone.
Large and small biotechnology companies alike are looking to partner or acquire them.
It could happen at any time, sparking an immediate windfall for shareholders.
If that happens this opportunity will disappear forever. And I’ll be forced to remove this presentation.
But regardless…
The orphan drug trend is gaining steam. And as more and more pharmaceutical companies shift to focus on drugs for genetic diseases the biggest winner will be the biotechnology stock I mentioned today.
You’ve seen the charts.
You’ve seen the increasing venture capital investment.
You’ve seen what the future of medicine looks like. How it could save your life or the life of a loved one. And the wealth to be claimed.
You can choose to ignore what you’ve just seen.
Or click on the “subscribe now” button below to get started.
Once you do, you’ll be taken to a special page where you can review everything that’s waiting for you.
